First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders
First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders
The primary purpose of this first-in-man study is to investigate whether a new drug for
 neurological disorders is safe and well-tolerated when administered orally to healthy adults
Key inclusion Criteria:

 -  Signed informed consent

 -  Healthy on the basis of physical examination,12-lead electrocardiogram and laboratory
 tests

 -  Males and females of non-childbearing potential, aged between 18 and 60 years (all
 inclusive)

 -  Women must have a negative serum pregnancy test at Screening and a negative urine
 pregnancy test predose on Day -1

 -  Body mass index (BMI) between 18.0 and 29.9 kg/m2 (inclusive)

 -  Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR)
 between 90-140 mmHg, 50-90 mmHg and 50-90 bpm (all inclusive), respectively

 Key exclusion Criteria:

 -  History or clinical evidence of any disease and/or existence of any surgical or
 medical condition which might interfere with the absorption, distribution, metabolism
 or excretion of the study treatment

 -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
 reactions

 -  Any circumstances or conditions, which, in the opinion of the Investigator, may affect
 full participation in the study or compliance with the protocol